Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of long-term ambrisentan treatment in inoperable chronic thromboembolic pulmonary hypertension
2012-001642-17Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ambrisentan in chronic thromboembolic pulmonary hypertension (CTEPH), sponsored by GSK. Primary endpoint: Primary safety and tolerability endpoint. Started Mar 2013; status: completed.
02
Drugs
ambrisentan
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on 2012-001642-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001642-17.